2Gaede P,Vedel P,Larsen N ,et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New Eng J Med ,2003, 348:383 - 393. 被引量：1
3Panzer C, Brieke A, Ruderman N. Prevention of type 2 diabetes and its macrovascular complications: whom, when, and how should we treat? Current Opin Endocfinol Diabetes,2003,10:229 -236. 被引量：1
4Grundy SM, Brewer Jr HB, Cleeman JI, et al. Definition of Metabolic Syndrome Report of the National Heart, Lung and Blood Institute/American Heart Association Conference. on Scientific Issues Retated to Definition. Circulation,2004,109:433 - 438. 被引量：1
6Einhom D, Reaven GM, Cobin RH, et al. American College Endocrinology position statement on the insulin resistance syndrom. Endocr Pract, 2003,9:237 -252. 被引量：1
6Olefsky JM. Treatment of insulin resistance with peroxisome proliferatoractivated receptor γ agonists. J Clin Invest, 2000, 106:467-472. 被引量：1
7Hotamisligil. G S. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes , 1999,107:119-125. 被引量：1
8Shulman. G I. Cellular mechanisms of insulin resistance. J Clin Invest, 2000,106:171-176. 被引量：1
9Hevener AL, Reichart D, Janez A. et al. Thiazolidinedione treatment prevents free fatty acid-Induced Insulin resistance in male wistar rats. Diabetes, 2001,50:2316-2322. 被引量：1
10Meyer MM, Levin K, Grimmsmann T, et al. Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of type 2 diabetes. Diabetes, 2002,51:2691-2697. 被引量：1
9Flier JS,Schere PE Adipose tussue from lipid storage compartment to endocrine organ[J].Dibetes,2005,54(Suppl I):6-7. 被引量：1
10Pyorala K,Lee Metal Reduction of coronary events by simvastatin in non-diabetic coronary heart disease with and withowt the metabolic syndrome:Subgroup analysis of the Scandinavian Simvastatin Survival stwdy[J].Diabetes,2003,52,A19. 被引量：1
